Learn more about ZOMETA^® in patients with

ZOMETA can work for patients like those you see in your practice

• Over 3 million patients have been treated with ZOMETA¹
• Only dosing every 3 to 4 weeks is proven to protect patients from the devastating effects
  of bone metastases^2-5
• Dosing ZOMETA less frequently than at the approved schedule results in a significant loss
  of efficacy⁶
• These case studies provide just a few examples of patients who need the bone protection
  of ZOMETA

The people depicted in the photos above are models and are being used for illustrative purposes only. The information presented is based on individual patient case studies. Clinical response to ZOMETA therapy may vary by patient.

References: 1. Data on file. Novartis Pharmaceuticals Corporation. 2. Rosen LS, Gordon D, Tchekmedyian NS,
et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumours: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100:2613-2621. 3. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-892. 4. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer.
2003;98:962-969. 5. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321. 6. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumours and bone metastases: analysis of a National Medical claims database. Cancer. 2008;113:1438-1445.